Toolbox Motor Validation

Five sub-domains of motor function have been identified for inclusion in the NIH Toolbox dexterity, strength, locomotion, endurance, and non-vestibular balance based on literature and expert interviews. Non-vestibular balance efforts have merged with vestibular balance and measures are being led by the balance team within the sensory domain. Candidate measures for each sub-domain have been identified and pre-tested with people across the age spectrum from 3-85. Pre-testing included an evaluation of feasibility, safety, instruction comprehension, ease of administration. During the pilot testing/validating phase of the study, motor function measures will be evaluated to: 1) determine equivalency with criterion measures in each sub-domain 2) ensure that the measures adequately discriminate between people of different skills levels, and 3) minimize floor and ceiling effects

Breast Cancer Survivors’ Beliefs and Preferences Regarding Technology-Supported Sedentary Behavior Reduction Interventions

Purpose: Less time spent in sedentary behaviors is associated with improved health and disease outcomes in breast cancer survivors. However, little is known about survivors’ interest in sedentary behavior reduction interventions and how to effectively reduce this risk behavior. The purpose of this study was to explore breast cancer survivors’ interest in and preferences for technology-supported sedentary behavior reduction interventions. Methods: Breast cancer survivors (n = 279; Mage = 60.7 (SD = 9.7)) completed a battery of online questionnaires. Descriptive statistics were calculated for all data. To examine potential relationships between demographic, disease and behavioral factors, and survivors’ interest in a technology-supported sedentary behavior reduction intervention, we conducted logistic regression analyses. These same factors were examined in relation to the perceptions of the effectiveness of such intervention using multiple regression analyses. Results: On average, survivors spent 10.1 (SD = 4.3) hours/day in sedentary activity. They believed prolonged periods of sedentary behavior were harmful to their health (87.0%) and that reducing sedentary behavior could improve their health (88.4%). Survivors believed they should move around after 30–60 (56.7%) or ≥ 60 (29.9%) minutes of sedentary behavior and indicated they were most likely to replace sedentary behaviors with walking around (97.1%) or walking in place (73.4%). The majority of survivors (79.9%) was interested in participating in a technology-supported sedentary behavior reduction intervention and indicated they would use a smartphone application (61.3%) 2–3 times/day (48.0%), 6 to 7 days/week (52.0%). Most survivors (73.5%) believed reminders would help them decrease sedentary behavior and preferred they be delivered after sitting for 60 minutes (60.5%) via vibrations on a wrist worn activity tracker (77.3%) or text messages (54.4%). Conclusions: Technology-supported sedentary behavior reduction interventions may be feasible and acceptable to breast cancer survivors. Data regarding user preferences for content, features, delivery mode and design will aid researchers in developing sedentary interventions that are potentially more relevant and effective from the outset

Mechanisms of disease in frontotemporal lobar degeneration: gain of function versus loss of function effects

Frontotemporal lobar degeneration (FTLD) is clinically, pathologically and genetically heterogeneous. The prototypical clinical syndromes are behavioural variant frontotemporal dementia (bvFTD), a disorder of behaviour and executive impairments, progressive non-fluent aphasia (PNFA), a disorder of expressive language, and semantic dementia (SD), a disorder of conceptual knowledge [Neary et al 1998]. A proportion of patients with any of these syndromes of FTLD can develop the amyotrophic form of motor neurone disease (MND) [Neary et al 1990, Strong et al], further emphasising clinical heterogeneity within FTLD, and highlighting the long known association with, and suspected pathogenetic links between, FTLD and MND

Additional file 7 of Implicating genes, pleiotropy, and sexual dimorphism at blood lipid loci through multi-ancestry meta-analysis

Additional file 7: Table S5. Lookup of all prioritized lipid genes in the Therapeutic Target Database 2022

Additional file 23 of Implicating genes, pleiotropy, and sexual dimorphism at blood lipid loci through multi-ancestry meta-analysis

Additional file 23: Table S15. Comparison of the sex-specific effects

Additional file 4 of Implicating genes, pleiotropy, and sexual dimorphism at blood lipid loci through multi-ancestry meta-analysis

Additional file 4: Table S3. Text mining results for the PoPS+ prioritized genes